

Effect of multidrug resistance 1/P-glycoprotein on the hypoxia-induced multidrug resistance of human laryngeal cancer cells

DAWEI LI¹, LIANG ZHOU², JIAMENG HUANG² and XIYAN XIAO²

¹Department of Otolaryngology - Head and Neck Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233; ²Department of Otolaryngology - Head and Neck Surgery, Affiliated Eye and Ear, Nose and Throat Hospital of Fudan University, Shanghai 200031, P.R. China

Received December 9, 2015; Accepted January 5, 2016

DOI: 10.3892/ol.2016.4749

Abstract. In a previous study, it was demonstrated that hypoxia upregulated the multidrug resistance (MDR) of laryngeal cancer cells to chemotherapeutic drugs, with multidrug resistance 1 (MDR1)/P-glycoprotein (P-gp) expression also being upregulated. The present study aimed to investigate the role and mechanism of MDR1/P-gp on hypoxia-induced MDR in human laryngeal carcinoma cells. The sensitivity of laryngeal cancer cells to multiple drugs and cisplatin-induced apoptosis was determined by CCK-8 assay and Annexin-V/propidium iodide staining analysis, respectively. The accumulation of rhodamine 123 (Rh123) in the cells served as an estimate of drug accumulation and was evaluated by flow cytometry (FCM). MDR1/P-gp expression was inhibited using interference RNA, and the expression of the MDR1 gene was analyzed using reverse transcription-quantitative polymerase chain reaction and western blotting. As a result, the sensitivity to multiple chemotherapeutic agents and the apoptosis rate of the hypoxic laryngeal carcinoma cells increased following a decrease in MDR1/P-gp expression ($P < 0.05$). Additionally, FCM analysis of fluorescence intensity indicated that the down-regulated expression of MDR1/P-gp markedly increased intracellular Rh123 accumulation ($P < 0.05$). Such results suggest that MDR1/P-gp serves an important role in regulating hypoxia-induced MDR in human laryngeal carcinoma cells through a decrease in intracellular drug accumulation.

Introduction

Laryngeal carcinoma is the second most prevalent malignancy located in the head and neck region (1). Chemotherapy is a common therapeutic approach for patients with advanced or metastatic laryngeal carcinoma; however, multidrug resistance (MDR) has been a major contributor to the failure of chemotherapy in patients presenting with this disease (2,3). The pathogenetic mechanisms underlying the regulation of MDR in laryngeal cancer cells currently remain unclear.

Hypoxia has been considered as an essential feature in human solid tumors, such as laryngeal cancer, and it affects a number of biological cell behaviors, including angiogenesis, apoptosis and resistance to therapy, occurring through the regulation of gene expression and modification of certain proteins (4). It has been reported that hypoxia induces drug resistance in various solid tumors (5-7). Similarly, it was confirmed in a previous study that hypoxia has an effect on the regulation of MDR in human laryngeal carcinoma cells (8). Therefore, hypoxia serves as a major obstacle in the development of cancer chemotherapy. Currently, further research is required to fully understand the regulatory mechanisms of MDR in hypoxic laryngeal cancer cells.

Multidrug resistance 1 (MDR1)/P-glycoprotein (P-gp), a plasma membrane glycoprotein encoded by the MDR1 gene, is a member of the adenosine triphosphate-binding cassette (ABC)-type transporter family. In a previous study, the upregulation of MDR1/P-gp expression was associated with a poorer prognosis in patients with human laryngeal cancer (9). It is understood that MDR1/P-gp serves a crucial role in regulating intracellular drug concentrations, consequently determining the drug sensitivity of human cells. Recently, MDR1/P-gp has been elucidated to be involved in the regulation of MDR in human laryngeal cancer cells (10,11), with the inhibition of MDR1/P-gp expression having been confirmed as an effective method to reverse MDR in such cells (11). Furthermore, previous data have demonstrated that MDR1/P-gp expression is significantly upregulated in response to hypoxia in laryngeal cancer cells (12). To the best of our knowledge, there are currently no existing studies that focus on the function and mechanism of MDR1/P-gp in the hypoxia-induced MDR observed in laryngeal cancer cells.

Correspondence to: Dr Dawei Li, Department of Otolaryngology - Head and Neck Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai 200233, P.R. China
E-mail: lidaweitree@163.com

Key words: cell hypoxia, P-glycoprotein, multiple drug resistance, laryngeal neoplasms

The present study aimed to investigate the role of MDR1/P-gp in the hypoxia-induced MDR of human laryngeal carcinoma cells and elucidate the mechanisms underlying this.

Materials and methods

Cell culture. Human laryngeal cancer Hep-2 and AMC-HN8 cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA) and the Asan Medical Center, Ulsan University College of Medicine (Seoul, Korea), respectively. Each cell line was cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), supplemented with 10% fetal bovine serum (HyClone; GE Healthcare Life Sciences, Logan, UT, USA), 100 IU/ml penicillin and 100 IU/ml streptomycin at 37°C with 5% CO₂.

Exposure to hypoxia. For hypoxic exposure, the Hep-2 and AMC-HN8 cells were incubated in a NU-4750 US Autoflow CO₂ Water-Jacketed Incubator (NuAire, Plymouth, MN, USA) at 37°C, with 1% O₂ and 5% CO₂ balanced by nitrogen.

Transfection of small interfering RNA (siRNA). The double strand siRNA oligonucleotide obtained to target the human MDR1 gene (sense, 5'-GGAAAAGAAACCAACUGU CTT-3'; and anti-sense, 5'-GACAGUUGGUUUCUUUC CTT-3') was synthesized by Shanghai GenePharma Co. Ltd. (Shanghai, China), as previously described (13). As a negative control, the cells were transfected with a non-specific control siRNA (sense, 5'-UUCUCCGAACGUGUCACGUTT-3'; and antisense, 5'-ACGUGACACGUUCGGAGAATT-3'; Shanghai GenePharma Co. Ltd.), which had no homology to any human transcripts on record. The cells were cultured in antibiotic-free medium for 24 h prior to transfection with 100nM siRNA using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). The cells were harvested and examined following a 24-h transfection period.

Reverse transcription-quantitative polymerase chain reaction (PCR) analysis. Total RNA was extracted from the laryngeal carcinoma cells using TRIzol® Reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocols. Subsequently, the isolated RNA was reverse-transcribed into complementary DNA (cDNA) using the PrimeScript® RT Reagent kit (Takara Bio, Inc., Otsu, Japan), as previously described (14). The primers used were as follows: MDR1 sense, 5'-CTTCAGGGTTTC ACATTGGC-3' and antisense, 5'-GGTAGTCAATGCTCC AGTGG-3'; and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) sense, 5'-CATCTTCCAGGAGCGAGA-3' and antisense, 5'-TGTTGTCATACTTCTCAT-3'. PCR amplification was performed in a 20- μ l final reaction mixture, including a diluted cDNA solution, 10 μ M of each primer and 10 μ l SYBR® Green PCR Master Mix (Thermo Fisher Scientific, Inc.) using the ABI 7900HT Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The thermal cycling conditions were as follows: One cycle at 95°C for 10 min and 40 cycles at 95°C for 15 sec and 60°C for 60 sec. The data were analyzed using the 2^{- $\Delta\Delta$ C_q} method, as previously described (15).

Western blot analysis. The laryngeal cancer Hep-2 and AMC-HN8 cells were harvested and lysed with cold radio-immunoprecipitation assay buffer (Sigma-Aldrich, St. Louis, MO, USA) for 30 min. Equal amounts of protein extract (25 μ g total protein) were loaded into sodium dodecyl sulfate polyacrylamide gel electrophoresis (5% stacking gel and 8% separating gel), followed by separation at 80 V for ~2 h and transferal onto Immobilon®-P PVDF Membranes (EMD Millipore, Billerica, MA, USA), blocked with 4% skimmed milk for 1.5 h at room temperature. Protein extracts were incubated overnight at 4°C with the primary antibodies [mouse monoclonal anti-human MDR1/P-gp (catalog no., ab3366; 1:200; Abcam, Cambridge, UK) and mouse monoclonal anti-human GAPDH (1:1,000; Sigma-Aldrich)], followed by incubation for 1 h with the secondary antibodies [horseradish peroxidase-conjugated anti-mouse secondary antibodies (1:5,000; Sigma-Aldrich)]. Finally, protein bands were detected by electrogenerated chemiluminescence according to the manufacturer's protocols (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA).

Cell cytotoxicity assay. The sensitivity of the Hep-2 and AMC-HN8 cells to fluorouracil (5-FU), cisplatin, doxorubicin, paclitaxel and gemcitabine was determined using a cell counting kit 8 (CCK-8) assay. The cells were plated in 96-well culture panels (Hep-2, 5x10³ cells/well; and AMC-HN8, 8x10³ cells/well), and following 12 h, the cells were treated with relevant doses of chemotherapeutic agents (5-fluorouracil: 0.1, 1, 10, 100 and 1000 μ g/ml; gemcitabine: 0.032, 0.32, 3.2, 32 and 320 μ g/ml; cisplatin: 0.03, 0.3, 3.0, 30 and 300 μ g/ml; adriamycin: 0.004, 0.04, 0.4, 4 and 40 μ g/ml); and paclitaxel: 0.09, 0.9, 9, 90 and 900 μ g/ml) and incubated for 48 h under normoxic or hypoxic conditions. The sensitivity of the cells to each agent was detected using CCK-8 assay, and the IC₅₀ was calculated as the concentration of each drug required to produce a 50% reduction in the number of cells.

Annexin-V/propidium iodide (PI) apoptosis assay. The apoptotic indices of the Hep-2 and AMC-HN8 cells were examined by flow cytometry (FCM). Cells in the log phase were grown in 6-well plates (Hep-2, 3x10⁵ cells/well; and AMC-HN8, 4x10⁵ cells/well) and cultured overnight at 37°C. The culture medium was then renewed, and the cells were incubated in normoxic or hypoxic conditions for 12 h. Cisplatin was added to each well with a final concentration of 2.5x10⁻⁹ M, and the cells were cultured in normoxic or hypoxic conditions for 48 h. Subsequently, 5 μ l (50 μ g/ml) Annexin-V-fluorescein isothiocyanate (FITC) was added to each well, and the cells were incubated for a further 10 min. The cells were washed twice with DMEM and then resuspended in 190 μ l Tris-hydrochloride buffer. Next, 5 μ l (20 μ g/ml) PI was added to the resuspended cells and cultured at 4°C for a further 10 min. The mean fluorescence intensity of Annexin-V-FITC/PI was measured by FCM. Finally, the apoptotic indices of the Hep-2 and AMC-HN8 cells were calculated by the mean fluorescence intensity.

Rhodamine 123 (Rh123) accumulation assay. Rh123 accumulation in the Hep-2 and AMC-HN8 cells was analyzed by FCM, which was performed as previously described (16).

Table I. Effect of MDR1/P-gp expression inhibition on the chemosensitivity of hypoxic Hep-2 cells.

Drug	IC ₅₀ , μg/ml		
	Untreated control	Negative control	MDR1-siRNA
Paclitaxel	3.90x10 ⁻² ±0.21x10 ⁻²	3.85x10 ⁻² ±0.26x10 ⁻²	7.61x10 ⁻³ ±0.39x10 ^{-3a}
5-FU	240.81±0.32	238.90±0.21	78.24±0.48 ^a
Doxorubicin	3.94±0.15	3.96±0.24	2.24±0.27 ^a
Gemcitabine	39.26±0.16	39.18±0.28	28.26±0.35 ^a
Cisplatin	9.10±0.10	8.82±0.12	4.48±0.36 ^a

Mean ± standard deviation of three individual experiments. ^aP<0.05 vs. untreated control and negative control. IC₅₀, half maximal inhibitory concentration; MDR1, multidrug resistance 1; siRNA, small interfering RNA; 5-FU, fluorouracil.

Table II. Effect of MDR1/P-glycoprotein expression inhibition on the chemosensitivity of hypoxic AMC-HN8 cells.

Drug	IC ₅₀ , μg/ml		
	Untreated control	Negative control	MDR1-siRNA
Paclitaxel	35.54x10 ⁻³ ±0.36x10 ⁻³	36.04x10 ⁻³ ±0.17x10 ⁻³	7.23x10 ⁻³ ±0.58x10 ^{-3a}
5-FU	230.34±0.64	232.48±0.92	71.53±0.82 ^a
Doxorubicin	3.72±0.22	3.87±0.35	2.12±0.19 ^a
Gemcitabine	36.40±0.32	35.58±0.29	21.48±0.13 ^a
Cisplatin	8.83±0.58	8.64±0.26	3.35±0.27 ^a

Mean ± standard deviation of three individual experiments. ^aP<0.05 vs. untreated control and negative control. IC₅₀, half maximal inhibitory concentration; MDR1, multidrug resistance 1; siRNA, small interfering RNA; 5-FU, fluorouracil.

The cell suspension was detected by a FACSCalibur Flow Cytometer (BD Biosciences, Franklin Lakes, NJ, USA) using 488 nm excitation. All the data were analyzed using Cell-Quest™ software (BD Biosciences).

Statistical analysis. Each experiment was repeated at least three times, and the data are presented as the mean ± standard deviation. Comparisons of quantitative variables were performed using Student's t-test or a one-way analysis of variance using SPSS software, version 13.0 (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Inhibition of MDR1 gene expression by RNA interference. In a previous study, it was confirmed that MDR1 gene expression in human laryngeal cancer cells was upregulated by hypoxia (12). In the present study, the Hep-2 and AMC-HN8 cells were transfected with either non-specific control siRNA (scrambled siRNA) or a double-strand siRNA oligonucleotide that targeted the MDR1 gene (MDR1-siRNA) for 24 h, followed by a 24-h incubation in hypoxic conditions. As presented in Fig. 1, compared with the negative or untreated controls, the protein and mRNA levels of the MDR1 gene in the hypoxic laryngeal cancer cells were significantly reduced following transfection with MDR1-siRNA (P<0.05).

Inhibition of MDR1/P-gp expression suppresses MDR in hypoxic laryngeal carcinoma cells. It has been previously demonstrated that hypoxia upregulates the sensitivity of human laryngeal cancer cells to multiple chemotherapeutic agents (8). In the present study, to allow for the investigation of the role of MDR1/P-gp in hypoxia-induced MDR, the Hep-2 and AMC-HN8 cells were transfected with MDR1-siRNA or scrambled siRNA for 24 h prior to incubation in hypoxic conditions. Subsequently, the drug sensitivity of the MDR1-siRNA group was compared to that of the negative or untreated control groups using a CCK-8 assay. As presented in Tables I and II, the sensitivity of the hypoxic laryngeal carcinoma cells to cisplatin, gemcitabine, paclitaxel, 5-FU and doxorubicin was significantly upregulated following the suppression of MDR1/P-gp expression (P<0.05).

MDR1/P-gp protects hypoxic laryngeal cancer cells from cisplatin-induced apoptosis. A previous study demonstrated that hypoxia enhances the rate of chemotherapy-induced apoptosis in laryngeal cancer cells (8). In the present study, FCM with Annexin-V/PI staining was utilized to assess the role of MDR1/P-gp in the hypoxic protection of Hep-2 and AMC-HN8 cells from cisplatin-induced apoptosis. It was observed that the rate of cisplatin-induced apoptosis was significantly increased under hypoxic conditions in the MDR1-siRNA transfected cells compared with the untreated or negative controls (P<0.05; Fig. 2).




Figure 1. Downregulation of MDR1 gene expression in hypoxic laryngeal cancer cells transfected with MDR1-siRNA. Hep-2 and AMC-HN8 cells were transfected with vectors containing either a MDR1 scrambled or MDR1 targeting sequence (MDR1-siRNA), and were then cultured in hypoxic conditions for 24 h. (A) MDR1 mRNA expression in the cells was analyzed by reverse transcription-quantitative polymerase chain reaction; **P<0.01 vs. empty and negative groups under hypoxia. MDR1/P-gp protein expression in the (B) Hep-2 and (C) AMC-HN8 cells was assessed by western blotting. (D) Quantification of western blotting. *P<0.05 vs. empty and negative groups. MDR1, multidrug resistance 1; siRNA, small interfering RNA; P-gp, P-glycoprotein; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.




Figure 2. Effect of MDR1/P-glycoprotein expression on the rate of cisplatin-induced apoptosis in hypoxic cells. The apoptotic percentage of the hypoxic (A) Hep-2 and (B) AMC-HN8 cells in the control groups and MDR1-siRNA group pre-treated with cisplatin (2.5×10^{-9} M). Data are presented as the mean \pm standard deviation from three independent experiments. *P<0.05 vs. empty and negative groups. MDR1, multidrug resistance 1; siRNA, small interfering RNA.




Figure 3. Effect of MDR1/P-glycoprotein on the accumulation of intracellular rhodamine 123 in hypoxic laryngeal cancer cells. (A) Hep-2 controls and Hep-2 MDR1-siRNA-transfected cells in hypoxic conditions. *P<0.05 vs. empty and negative groups. (B) AMC-HN8 controls and AMC-HN8 MDR1-siRNA-transfected cells in hypoxic conditions. *P<0.05 vs. empty and negative groups. Data are presented as the mean \pm standard deviation from three independent experiments. N, normoxia; H, hypoxia; MDR1, multidrug resistance 1; siRNA, small interfering RNA.

MDR1/P-gp downregulates drug accumulation in hypoxic laryngeal cancer cells. A previous study demonstrated that hypoxia significantly reduces the intracellular drug accumulation in laryngeal carcinoma cells (8). In the current study, the effect of MDR1/P-gp expression on intracellular drug accumulation in hypoxic Hep-2 and AMC-HN8 cells was evaluated using FCM to detect the fluorescence intensity of intracellular Rh123 accumulation. As presented in Fig. 3, the laryngeal carcinoma cells exposed to hypoxic conditions had significantly decreased Rh123 accumulation ($P < 0.05$). Furthermore, the inhibition of MDR1/P-gp expression in the hypoxic Hep-2 and AMC-HN8 cells transfected with MDR1-siRNA significantly increased the intracellular accumulation of Rh123 ($P < 0.05$; Fig. 3).

Discussion

Despite the wide application of chemotherapeutic agents for the treatment of human laryngeal cancer, MDR remains a major therapeutic obstacle. The hypoxic microenvironment has been recognized as a common phenomenon in the tissues of human solid tumors. Currently, there is increasing evidence suggesting that hypoxic cells are somewhat resistant to conventional chemotherapy in various human malignancies (7,17,18). A previous study confirmed that the sensitivity of laryngeal cancer cells to multiple chemotherapeutic drugs may be reduced by hypoxia (8). However, the regulatory mechanism underlying hypoxia-induced MDR in human laryngeal carcinoma cells remains to be identified.

MDR1/P-gp is a member of the ABC-type transporter family and has been considered as a biofunctional regulator of MDR in a series of human tumor cells (19-21). In a previous study, it was demonstrated that the expression of MDR1/P-gp in human laryngeal cancer tissues was associated with malignant progression and metastasis (9). Furthermore, several studies have reported that MDR1/P-gp may serve a crucial role in the regulation of MDR in laryngeal cancer cells (10,11). Zhigang *et al* (11) observed that the inhibition of MDR1/P-gp expression served as an effective method to reverse MDR in laryngeal cancer cells. Similarly, certain studies have identified that hypoxia may contribute to MDR through the upregulation of MDR1/P-gp expression in human tumor cells (22,23). By contrast, Song *et al* (24) indicated that MDR1/P-gp may not be involved in hypoxia-induced MDR in non-small cell lung cancer cells. Another previous study confirmed that hypoxia significantly enhances the expression of MDR1/P-gp in laryngeal carcinoma cells (12), and the current study demonstrated that the inhibition of MDR1/P-gp expression significantly increased the sensitivity of laryngeal cancer cells to multiple drugs in hypoxic environments. Therefore, further research has verified that the inhibition of MDR1/P-gp expression upregulates the apoptosis rate of hypoxic laryngeal cancer cells induced by chemotherapy. This suggests that MDR1/P-gp may be partly involved in the hypoxia-induced MDR observed in laryngeal cancer cells, and the suppression of MDR1/P-gp expression may be considered as an effective approach to achieve MDR reversal. The differences noted between the aforementioned studies may be due to intrinsic differences in the regulatory mechanisms of MDR in numerous types of tumor cells.

Theoretically, MDR1/P-gp, as an energy-dependent membrane efflux pump, has an effect on the drug sensitivity of human cells by regulating intracellular drug concentrations (25,26). In a previous study, it was demonstrated that hypoxia markedly reduced drug accumulation in laryngeal cancer cells (8). In practice, the results of the present study indicated that inhibition of MDR1/P-gp expression results in the downregulation of the transport function in hypoxic laryngeal cancer cells, leading to increased intracellular drug concentration and suppression of hypoxia-induced MDR. Similar to the results of Wartenberg *et al* (22) and Xia *et al* (23), the data from the current study suggested that MDR1/P-gp may partly contribute to hypoxia-induced MDR in human laryngeal cancer cells through the regulation of drug transport. However, further research is necessary to determine the regulatory mechanisms underlying MDR1/P-gp expression in hypoxic laryngeal cancer cells.

In conclusion, the present study indicates that MDR1/P-gp expression serves an important role in the mediation of MDR in hypoxic laryngeal carcinoma cells. The results have provided evidence that a decrease in intracellular drug concentration may explain how MDR1/P-gp contributes to the MDR of hypoxic laryngeal cancer cells. Therefore, targeting the MDR1 gene may be a potentially beneficial therapeutic strategy for the reversal of hypoxia-induced MDR in human laryngeal cancer cells.

Acknowledgements

The authors would like to thank Professor Jin-ke Cheng and Professor Xue-mei Tong, from the Department of Biochemistry and Molecular Biology, Shanghai Jiao Tong University School of Medicine (Shanghai, China), for providing technical assistance. This study was funded by the China Postdoctoral Science Foundation (grant no. 2013M541466).

References

1. Chu EA and Kim YJ: Laryngeal cancer: Diagnosis and preoperative work-up. *Otolaryngol Clin North Am* 41: 673-695, v, 2008.
2. Liu HC, Chen GG, Vlantis AC, Tong MC and van Hasselt CA: Chemotherapy for laryngeal cancer - an apoptotic approach. *Curr Drug Targets* 9:878-886, 2008.
3. Bar-Ad V, Palmer J, Yang H, Cognetti D, Curry J, Luginbuhl A, Tuluc M, Campling B and Axelrod R: Current management of locally advanced head and neck cancer: The combination of chemotherapy with locoregional treatments. *Semin Oncol* 41:798-806, 2014.
4. Wang GL, Jiang BH, Rue EA and Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. *Proc Natl Acad Sci USA* 92: 5510-5514, 1995.
5. Wohlkoenig C, Leithner K, Deutsch A, Hrzenjak A, Olschewski A and Olschewski H: Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells. *Cancer Lett* 308: 134-143, 2011.
6. Yoshida S, Ito D, Nagumo T, Shirota T, Hatori M and Shintani S: Hypoxia induces resistance to 5-fluorouracil in oral cancer cells via G(1) phase cell cycle arrest. *Oral Oncol* 45: 109-115, 2009.
7. Huang L, Ao Q, Zhang Q, Yang X, Xing H, Li F, Chen G, Zhou J, Wang S, Xu G, *et al*: Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha. *J Cancer Res Clin Oncol* 136: 447-456, 2010.
8. Li DW, Dong P, Wang F, Chen XW, Xu CZ and Zhou L: Hypoxia induced multidrug resistance of laryngeal cancer cells via hypoxia-inducible factor-1 α . *Asian Pac J Cancer Prev* 14: 4853-4858, 2013.

9. Li DW, Gao S, Shen B and Dong P: Effect of apoptotic and proliferative indices, P-glycoprotein and survivin expression on prognosis in laryngeal squamous cell carcinoma. *Med Oncol* 28 (Suppl 1): S333-S340, 2011.
10. Li L, Jiang AC, Dong P, Wan Y and Yu ZW: The characteristics of Hep-2 cell with multiple drug resistance induced by Taxol. *Otolaryngol Head Neck Surg* 137: 659-664, 2007.
11. Zhigang H, Qi Z, Jugao F, Xiaohong C, Wei Z, Hong W, Hu H, Na M, Zheng Y and Demin H: Reverse multidrug resistance in laryngeal cancer cells by knockdown MDR1 gene expression. *J Otolaryngol Head Neck Surg* 38: 440-448, 2009.
12. Xie J, Li DW, Chen XW, Wang F and Dong P: Expression and significance of hypoxia-inducible factor-1 α and MDR1/P-glycoprotein in laryngeal carcinoma tissue and hypoxic Hep-2 cells. *Oncol Lett* 6: 232-238, 2013.
13. Sowter HM, Raval RR, Moore JW, Ratcliffe PJ and Harris AL: Predominant role of hypoxia-inducible transcription factor (Hif)-1 α versus Hif-2 α in regulation of the transcriptional response to hypoxia. *Cancer Res* 63: 6130-6134, 2003.
14. Li DW, Zhou L, Jin B, Xie J and Dong P: Expression and significance of hypoxia-inducible factor-1 α and survivin in laryngeal carcinoma tissue and cells. *Otolaryngol Head Neck Surg* 148: 75-81, 2013.
15. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^{-Delta Delta C(T)} Method. *Methods* 25: 402-408, 2001.
16. Ludescher C, Thaler J, Drach D, Drach J, Spitaler M, Gattringer C, Huber H and Hofmann J: Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123. *Br J Haematol* 82: 161-168, 1992.
17. Zhu H, Chen XP, Luo SF, Guan J, Zhang WG and Zhang BX: Involvement of hypoxia-inducible factor-1- α in multidrug resistance induced by hypoxia in HepG2 cells. *J Exp Clin Cancer Res* 24: 565-574, 2005.
18. Liu L, Ning X, Sun L, Zhang H, Shi Y, Guo C, Han S, Liu J, Sun S, Han Z, *et al*: Hypoxia-inducible factor-1 α contributes to hypoxia-induced chemoresistance in gastric cancer. *Cancer Sci* 99: 121-128, 2008.
19. Huang C, Xu D, Xia Q, Wang P, Rong C and Su Y: Reversal of P-glycoprotein-mediated multidrug resistance of human hepatic cancer cells by Astragaloside II. *J Pharm Pharmacol* 64: 1741-1750, 2012.
20. Hao YX, He ZW, Zhu JH, Shen Q, Sun JZ, Du N and Xiao WH: Reversal of multidrug resistance in renal cell carcinoma by short hairpin RNA targeting MDR1 gene. *Chin Med J (Engl)* 125: 2741-2745, 2012.
21. Jia M, Hu J, Li W, Su P, Zhang H, Zhang X and Zhou G: Trps1 is associated with the multidrug resistance of osteosarcoma by regulating MDR1 gene expression. *FEBS Lett* 588: 801-810, 2014.
22. Wartenberg M, Ling FC, Müschen M, Klein F, Acker H, Gassmann M, Petrat K, Pütz V, Hescheler J and Sauer H: Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. *FASEB J* 17: 503-505, 2003.
23. Xia S, Yu SY, Yuan XL and Xu SP: Effects of hypoxia on expression of P-glycoprotein and multidrug resistance protein in human lung adenocarcinoma A549 cell line. *Zhonghua Yi Xue Za Zhi* 84: 663-666, 2004 (In Chinese).
24. Song X, Liu X, Chi W, Liu Y, Wei L, Wang X and Yu J: Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1 α gene. *Cancer Chemother Pharmacol* 58: 776-784, 2006.
25. Kimura Y, Matsuo M, Takahashi K, Saeki T, Kioka N, Amachi T and Ueda K: ATP hydrolysis-dependent multidrug efflux transporter: MDR1/P-glycoprotein. *Curr Drug Metab* 5:1-10, 2004.
26. Ueda K: Molecular mechanisms for drug transport by MDR1/P-glycoprotein. *Tanpakushitsu Kakusan Koso* 42: 1263-1272, 1997 (In Japanese).